Objective: Although rapid progression of coronary atherosclerosis was observed in chronic cocaine users, it is unknown whether reduced cocaine use retards the progression of atherosclerosis. We investigated whether reduced cocaine use over a 12-month period was associated with coronary plaque regression in cocaine users. Methods: Fifteen African American chronic cocaine users with previously coronary computed tomography angiography (CCTA)-confirmed >50% coronary stenosis in Baltimore, Maryland, were enrolled in a study to investigate whether reduced cocaine use is associated with changes in coronary plaque burden over a 12-month period of cash-based incentive intervention, which was implemented to systematically reinforce cocaine abstinence. In addition to previous CCTA (preintervention), CCTA was performed at the intervention baseline and at postintervention. Plaque analyses were performed to determine the trajectory of plaque changes in the absence of intervention by comparing the preintervention with the intervention baseline studies; the trajectory of plaque changes associated with the intervention by comparing the intervention baseline with the postintervention studies; and (3) whether reduced cocaine use was independently associated with changes in coronary plaque burden. Results: During the 12-month cash-based incentive intervention period, cocaine use in participants was lower. at preintervention, intervention baseline, and postintervention, respectively. Multivariable generalized estimating equation analysis showed that both total plaque and noncalcified plaque indices at preintervention were significantly lowered as compared with intervention baseline levels; both total plaque and noncalcified plaque indices after intervention were significantly lowered as compared with intervention baseline levels; and reduced cocaine use was independently associated with lower total plaque volume index (P < 0.0001) and noncalcified plaque volume index (P ¼ 0.010). Conclusions: Our findings suggest that continued cocaine use may be associated with noncalcified plaque progression, whereas reduced cocaine use may be associated with noncalcified plaque regression. Larger studies are needed to confirm these findings.
Objective: Although rapid progression of coronary atherosclerosis was observed in chronic cocaine users, it is unknown whether reduced cocaine use retards the progression of atherosclerosis. We investigated whether reduced cocaine use over a 12-month period was associated with coronary plaque regression in cocaine users. Methods: Fifteen African American chronic cocaine users with previously coronary computed tomography angiography (CCTA)-confirmed >50% coronary stenosis in Baltimore, Maryland, were enrolled in a study to investigate whether reduced cocaine use is associated with changes in coronary plaque burden over a 12-month period of cash-based incentive intervention, which was implemented to systematically reinforce cocaine abstinence. In addition to previous CCTA (preintervention), CCTA was performed at the intervention baseline and at postintervention. Plaque analyses were performed to determine the trajectory of plaque changes in the absence of intervention by comparing the preintervention with the intervention baseline studies; the trajectory of plaque changes associated with the intervention by comparing the intervention baseline with the postintervention studies; and (3) whether reduced cocaine use was independently associated with changes in coronary plaque burden. Results: During the 12-month cash-based incentive intervention period, cocaine use in participants was lower. The medians of noncalcified plaque indices were 37.8 (interquartile range [IQR] 29.3-44.0), 43.1 , and 38.7 (IQR 31.2-46.8) mm 2 at preintervention, intervention baseline, and postintervention, respectively. Multivariable generalized estimating equation analysis showed that both total plaque and noncalcified plaque indices at preintervention were significantly lowered as compared with intervention baseline levels; both total plaque and noncalcified plaque indices after intervention were significantly lowered as compared with intervention baseline levels; and reduced cocaine use was independently associated with lower total plaque volume index (P < 0.0001) and noncalcified plaque volume index (P ¼ 0.010). Conclusions: Our findings suggest that continued cocaine use may be associated with noncalcified plaque progression, whereas reduced cocaine use may be associated with noncalcified plaque regression. Larger studies are needed to confirm these findings.
Key Words: cash-based incentive intervention, cocaine use, contrast-enhanced coronary CT angiography, coronary plaque regression, noncalcified coronary plaque volume index (J Addict Med 2017; 11: 126-137) E xtracted from the leaves of the Erythroxylon coca plant, cocaine is a psychomotor stimulant that has been used worldwide (Benzaquen et al., 2001) , and 1 of the most commonly used illicit drugs worldwide and in the United States. It is estimated worldwide that up to 20 millions of people between the ages of 15 and 64 years used cocaine in 2009 (Degenhardt and Hall, 2012) . Despite many efforts and initiatives to control cocaine use, the United States still faces an epidemic of its use by adolescents and young adults from all socioeconomic backgrounds. In 2013, there were 1.5 million chronic cocaine users aged 12 years or older, or 0.6% of the US population (Substance Abuse and Mental Health Services Administration, 2014) .
Cocaine has been implicated in accelerating the development of atherosclerosis (Dressler et al., 1990; Benzaquen et al., 2001; Ebersberger et al., 2013) . Nevertheless, most studies are cross-sectional, retrospective chart reviews, or based on autopsy findings. The exact underlying mechanisms linking cocaine use with clinical and subclinical coronary atherosclerosis are not well-defined. A large body of literature has demonstrated that chronic cocaine use is associated with several clinical cardiovascular complications, including angina pectoris, myocardial infarction, and cardiac death (Dressler et al., 1990; Benzaquen et al., 2001; Aquaro et al., 2011; Degenhardt and Hall, 2012) . Despite pathological, clinical, and epidemiological evidence suggesting that chronic cocaine use is associated with the development and progression of coronary atherosclerosis, the existing evidence that cocaine induces and/or accelerates coronary atherosclerosis remains controversial because of differences in study design, study population, and the statistical methods employed (Dressler et al., 1990; Benzaquen et al., 2001; Aquaro et al., 2011; Chang et al., 2011; Ebersberger et al., 2013) .
Since 2000, we recruited and followed up approximately 1500 African Americans (AAs) to investigate the effects of cocaine use and other factors on subclinical coronary atherosclerosis in Baltimore, Maryland. We reported that long-term cocaine use is independently associated with obstructive coronary stenosis (Lai et al., 2008) and that duration of cocaine use is associated with levels of an endothelial dysfunction biomarker, endothelin-1 (ET-1) (Tai et al., 2012) . ET-1 has proinflammatory properties and is associated with cardiovascular risk (Bossard et al., 2015) .
We further found that cocaine use can be reduced with the use of a cash-based incentive intervention, and that reduced cocaine use is associated with reduced ET-1 levels .
These surprising results prompted us to hypothesize that reduced cocaine use potentially retards coronary plaque progression in chronic cocaine users with existing coronary plaque burden. To test this hypothesis, we enrolled 15 chronic cocaine users with coronary computed tomography angiography (CCTA)-confirmed prior >50% coronary stenosis from AAs who participated in 1 of our CCTA studies, and implemented a 12-month cash-based incentive intervention to reduce cocaine use. Thus, 3 sets of demographic, behavioral, laboratory, and imaging data were collected: preintervention, which is the last research visit before the intervention baseline; intervention baseline; and the 12-month postintervention follow-up. The objectives of this preliminary study were to examine whether coronary plaque burden increases over the period in which no intervention was performed (from the preintervention to intervention baseline period); whether coronary plaque burden decreases with reduced cocaine use over the period in which cash-based incentive intervention was available (from intervention baseline to postintervention); and whether reduced cocaine use was independently associated with changes in coronary plaque burden.
METHODS

Study Design and Participants
Between March and June 2014, 15 AA chronic cocaine users (3 women and 12 men) were consecutively enrolled from our ongoing study into a preliminary study to explore whether a change in cocaine use is associated with a change in coronary plaque burden in chronic cocaine users with contrastenhanced CCTA-confirmed >50% obstructive coronary plaque at the Johns Hopkins Hospital, Baltimore, Maryland, USA.
Inclusion criteria were as follows: participation in our ongoing longitudinal study investigating the adverse effect of cocaine use and other factors on subclinical atherosclerosis in AAs, Baltimore, Maryland with the use of contrast-enhanced CCTA; aged 25 years or older; the presence of at least 1-vessel >50% obstructive coronary plaque, confirmed by contrastenhanced CCTA; chronic cocaine use defined as use of cocaine by any route for at least 6 months, administered at least 4 times a month; and self-reported recent cocaine use, confirmed by a positive urine test for cocaine or benzoylecgonine during the initial screening visit, and fulfilling diagnostic criteria for cocaine dependence on a computerized version of the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 4th Edition axis I disorders (SCID). Exclusion criteria were as follows: any evidence of clinical coronary artery disease (CAD) or any symptoms believed to be related to cardiovascular disease; history of serious physical disease or current physical disease, chronic obstructive pulmonary disease, seizure, head trauma or central nervous system tumors, or current or past histories of serious psychiatric disorder (ie, axis I, Diagnostic and Statistical Manual of Mental Disorders, 4th Edition), other than substance abuse or dependence; infrequent cocaine users (fewer than 4 times a month, consecutive 6 months); pregnancy or child-bearing potential and not using effective birth control measures or the intent to become pregnant during the follow-up period; chronic kidney disease with an estimated glomerular filtration rate of <60 mL/min/1.73 m 2 ; ever on statin therapy; and contraindication to CT scans, including a history of contrast allergy.
The Committee on Human Research at the Johns Hopkins School of Medicine approved the study protocol and all study participants provided written informed consent. All procedures used in this study were in accordance with institutional guidelines.
Procedures
Interview, Medical Chart Review, Physical and Laboratory Examinations
At a time before the current investigation (preintervention), baseline of the intervention, and 12-month after intervention (postintervention), the following data were acquired in all study participants at research visits:
A detailed interview was conducted to obtain information regarding sociodemographic characteristics, medical history; behaviors, including alcohol consumption, drug use, and cigarette smoking; and medications. For HIV-positive participants, detailed information regarding HIV-related risk factors, duration of known HIV infection, and medications, including antiretroviral therapy (ART) use, was also collected. A medical chart review was used to confirm the information on medical history and medications provided by the study participants. A physical examination was performed and vital signs were recorded. Routine clinical laboratory blood chemistry tests were conducted. The following laboratory tests were also performed at each of the preintervention, intervention baseline, and postintervention visits: total serum cholesterol, triglycerides, high-density lipoprotein
Anthropometry and Blood Pressure Measurement
Blood pressures were measured with a standard mercury sphygmomanometer (average of 3 measurements). Height and weight, and also waist and hip circumferences were recorded.
Phlebotomy
An approximate 30-cc blood sample was drawn after a fasting interval of at least 12 hours.
ET-1 Assay
Extraction of plasma, assay, and calculation of results all followed the procedures specified for ELISA kit of ET-1 (R&D Systems, Inc., Minneapolis, MN). Standards, control, and the samples were assayed simultaneously in duplicate. The within-run coefficient of variation was 5%.
Voucher-based Incentive Interventions
The voucher-based inventive program was described previously . Briefly, a voucher-based method was used to reinforce cocaine abstinence. Voucher value escalates with longer episodes of abstinence. The voucherbased incentive program employed a management procedure that systematically reinforces cocaine abstinence, with features modeled after the escalating voucher incentive program developed by Higgins et al. (1993) . Points (1 point ¼ $1) were awarded for cocaine-negative test results. The number of points earned increased with the duration of abstinence and therefore rewards prolonged abstinence (maximum reward $100). There is also a ''reset-penalty'' where, in case of a positive urine test, not only are the points not awarded, but the escalating voucher values are reset again. Specifically, should drug use be detected via submission of a cocaine-positive urine sample, the participant will need to re-start the incentive program at the week 1 level and proceed again through the weekly steps. Not only does avoidance of the reset serve as a motivator for continued abstinence, but the return to more intensive monitoring is a clinically indicated response to evidence of drug relapse.
The frequency of urine tests decreases over time once a stable period of abstinence has been established. Specifically, in the first 4 weeks, participants will be asked to provide urine tests twice a week, and will earn $10 if 2 urine tests are both negative. In weeks 2 and 3, the participant will earn $20 for 2 negative urine tests, and will earn $30 for 2 negative urine tests in week 4. In weeks 5 to 8, only 1 urine test per week is required and potential earnings increase from $30 to $40 per week. After week 8, when a stable period of abstinence has been established, frequency of urine collection continues to decline with biweekly testing in weeks 8 to 16, and then once monthly testing after week 16. To counteract the decreased frequency of reinforcement with longer time between testing, value of the potential earnings increases to $80 with biweekly testing in weeks 10 to 16 and $100 with once-monthly testing in weeks 20 to 52. Earned money will be distributed immediately after each negative urine test in the form of a check.
Doing so provides immediate acknowledgement and reinforcement for the negative test. After money is earned, it belongs to the participant and is never taken back irrespective of subsequent drug use or other adverse behaviors.
Urine Benzoylecgonine Test
Urine tests were scheduled in advance. Urine samples were collected under observation of a same-sex research assistant, and the temperature of the sample examined to confirm its validity. Cocaine metabolite quantitation was conducted using an immunochromatography rapid drug test (DOA 1 Panel Dip Card -COC, MP Biomedicals, Solon, OH). This was used as a preliminary test result for the voucher-based intervention. Samples were also stored for quantitative urine analysis (Preston et al., 1997) . Missing samples were considered positive.
Reduction in Cocaine Use
According to questionnaire data, all the study participants used cocaine daily (the mean times of cocaine use per day was 2.9 AE 2.0 times/d, ranged from 1 to 7 times/d) at intervention baseline. Thus, reduction in cocaine use at postintervention was defined as 365 days À cumulative urine positive days during the 12-month intervention period according to urine tests.
Days of cocaine use are calculated as follows: in the first 4 weeks, participants will be asked to provide urine tests twice a week, and a positive urine result was calculated as 3.5 days of cocaine use. In weeks 5 to 8, only 1 urine test per week is required and a positive urine result was calculated as 7 days of cocaine use. In weeks 9 to 16, frequency of urine collection continues to decline with biweekly testing and a positive urine result was calculated as 14 days of cocaine use. After week 16, one urine test per month is required and a positive urine result was calculated as 30 days of cocaine use.
Contrast-enhanced CCTA
Cardiac CT scans were performed at preintervention, intervention baseline, and at the 12-month follow-up on a Siemens second-generation, 128-slice, dual-source CT (Somatom Definition Flash, Siemens Healthcare, Forchheim, Germany). No premedication was used. After a test bolus application to optimize the acquisition timing for the participant (10 cc bolus of contrast), CT angiography was performed. The scan parameters were 100 to 120 kVp (depending on the patient's size), Care Dose quality reference standard of 320 mAs (Care Dose 4D was used to minimize radiation dose), rotation time was 0.28 seconds, collimation was 128 Â 0.6 mm, and average acquisition time was under 5 seconds (heart rate-dependent). Scan data were reconstructed with .75 mm thickness at 0.5 mm reconstruction spacing using a B26ASA and B30f reconstruction kernel with iterative reconstruction. The scan protocol used 80 to 100 mL of an iso-osmolar contrast agent (Vispaque-320, GE Medical Systems) injected at 5 to 6 cc/s. Images for calcium scoring were obtained at precontrast (120 kVp, 3 mm slice thickness).
All images were interpreted by a radiologist with board certification in cardiac CT interpretation. Medis Medical Imaging Systems, Leiden, the Netherlands) (Fig. 1A) . The software has been validated against intravascular ultrasound (Park et al., 2015) , and was used extensively in clinical studies (Papadopoulou et al., 2012; Auscher et al., 2015; Ferencik et al., 2015; Rodriguez et al., 2015) .
The image analysts were blinded to participants' characteristics. The coronary tree was automatically extracted, and each of the major vessels (ie, the left anterior descending artery, the left circumflex artery, and the right coronary artery) was individually analyzed from the ostium to the point at which the internal vessel caliber decreased to <2.0 mm, exclusive of focal stenosis. Segmentation was performed according to American Heart Association nomenclature (Cerqueira et al., 2002) . Segments with image artifacts or stents were excluded. Automated longitudinal contouring of the inner lumen and outer wall was performed, and results were manually adjusted when clear deviations were noted. Results of automated contouring of the inner lumen and outer wall were also reviewed on transverse reconstructed cross-sections of the artery on a section-bysection basis at 0.5-mm increments (Rodriguez et al., 2015) . Lumen attenuation was adaptively corrected on an individualscan basis by using gradient filters in combination with the intensity values in the arteries, allowing for comparison between data sets (Park et al., 2015) . Total plaque volume (calcified plus noncalcified plaque volume) was calculated by subtracting the lumen volume from the outer wall volume. The plaque burden per unit length was calculated as segmental plaque volume (in mm 3 )/length (in mm) of the corresponding segment, yielding the total plaque volume index (in mm 2 ); noncalcified plaque volume index was calculated as the total volume index minus the calcified plaque volume index (in mm 2 ) (Rodriguez et al., 2015) .
Statistical Analysis
Statistical analysis was performed with SAS 9.4 (SAS Institute, Cary, NC). All continuous parameters were summarized by medians and interquartile ranges (IQRs), and all categorical parameters were summarized as proportions. To compare differences between intervention baseline and postintervention for demographic and clinical characteristics, laboratory parameters, and other factors, the nonparametric Wilcoxon 2-sample test was used for continuous variables and the Fisher exact test was employed for categorical variables.
Data from 3 visits (preintervention, intervention baseline, and postintervention) were used to perform longitudinal analysis. To examine whether coronary plaque burden increased over the period in which no intervention was performed (from the preintervention to intervention baseline period), and whether coronary plaque burden decreased with reduced cocaine use over the period in which cash-based incentive intervention was available (from intervention baseline to postintervention), a generalized estimating equation (GEE) model with the time variable as covariate of interest was used (Liang and Zeger, 1986) . Two indicator variables, preintervention visit versus otherwise, and postintervention versus otherwise, were created (intervention baseline visit as the reference). Univariable GEE analysis was performed to explore crude association between change in coronary plaque FIGURE 1. Mean cumulative days of cocaine use, median CRP, and median endothelin-1 over time. A, At preintervention and intervention baseline, we assumed that all participants used cocaine 365 days a year (mean AE SD ¼ 365 AE 0). At postintervention, the mean cumulative days of cocaine use was 50.4 AE 95.3 days, which was significantly reduced compared with that at intervention baseline (365 AE 0 days) (P < 0.0001, paired t test). B, The median CRP levels were 1.5 (IQR 0.7, 3.7) mg/dL for preintervention, 1.8 (IQR 0.6, 4.5) mg/dL for intervention baseline, and 1.6 (IQR: 0.1, 7.5) mg/dL, respectively. There was no statistical difference in CRP between intervention baseline and postintervention (P ¼ 0.24, Wilcoxon signed-rank test). C, The median endothelin-1 levels were 1.43 (IQR 1.11, 1.94) pg/mL for preintervention, 1.53 (IQR 1.35, 2.25) pg/mL for intervention baseline, and 1.26 (IQR 0.96, 1.52) pg/mL for postintervention, respectively. There was statistical difference in endothelin-1 between intervention baseline and postintervention (P ¼ 0.003, Wilcoxon signed-rank test). burden (total plaque volume index, calcified plaque volume index, and noncalcified plaque volume index) and time. A multivariable GEE model was used to adjust for potential confound factors, including preintervention plaque burden, the 2013 American College of Cardiology/American Heart Association (ACC/AHA) cardiovascular risk score (Goff et al., 2014) , and CRP levels. To examine whether reduced cocaine use was independently associated with changes in coronary plaque burden, a variable, reduction in cocaine use, defined as 365 days À cumulative urine positive days during the 12-month period, was included in the GEE models. Univariable GEE analysis was performed to explore crude association between change in coronary plaque burden (total plaque volume index, calcified plaque volume index, and noncalcified plaque volume index) and reduction in cocaine use. A multivariable GEE model was used to adjust for potential confound factors, including the above-mentioned time variable, preintervention plaque burden, the 2013 ACC/AHA cardiovascular risk score, and CRP levels. The P values reported are 2-sided. A P value <0.05 indicated statistical significance.
RESULTS
General Characteristics
The demographics and clinical characteristics of the 15 study participants are presented in Table 1 . The median age was 49 years and 20% were women. Among the 15 participants, 12 were HIV-infected. The median duration of cocaine use was 20 (IQR 7-30) years. The median time interval between preintervention and intervention baseline was 3.99 (IQR 2.41-7.11) years, whereas the median time interval between intervention baseline and postintervention was 1.04 (IQR 0.78-1.04) years.
Reduction in Cocaine Use, CRP, and Endothelin-1
According to self-report data from questionnaires, all the study participants used cocaine daily at intervention baseline. During the 12-month intervention, the mean cumulative days of cocaine use was 50 (SD 95) days, and median was 7 (IQR 0-35) days. The reduction in cocaine use during the intervention period was statistically significant (P < 0.0001; Fig. 2 ). CRP and ET-1 over time are presented in Figure 2 and Table 1 .
The median ET-1 levels were 1.43 (IQR 1.11, 1.94) pg/mL, 1.53 (IQR 1.35, 2.25) pg/mL, and 1.26 (IQR 0.97, 1.52) pg/mL for the preintervention, intervention baseline, and postintervention, respectively. The ET-1 at postintervention was significantly lower than that at intervention baseline (P ¼ 0.003). The median CRP levels were 1.5 mg/dL (IQR 0.7-3.7), 1.8 mg/dL (IQR 0.6, 4.5) pg/mL, and 1.6 mg/dL (IQR 0.1, 7.5) pg/mL for the preintervention, intervention baseline, and postintervention, respectively. The CRP at postintervention was not significantly lower than that at intervention baseline (P ¼ 0.24). Thus, the upward trajectories of the ET-1 and CRP levels, that is, between the preintervention and intervention baseline periods, were interrupted during the 12-month intervention period of reduced cocaine use.
Coronary Plaque Burden Over Time
The medians with IQRs of coronary plaque burden over time are presented in Table 1 and Figure 3 . Total coronary plaque volume index, calcified plaque volume index, and noncalcified plaque volume index appeared to increase from preintervention to intervention baseline, and noncalcified plaque volume index seemed to decrease from intervention baseline to postintervention. However, none of these differences was statistically significant.
Changes in Coronary Plaque Burden Over Time
Total Plaque Volume
By univariable GEE analysis, total plaque volume index at intervention baseline was significantly higher as compared with preintervention level (P ¼ 0.026; Table 2 ). After controlling for preintervention total plaque volume index, the 2013 ACC/AHA-defined cardiovascular risk, and CRP, total coronary plaque volume index at intervention baseline remained higher as compared with preintervention level (P ¼ 0.048; Table 2 ). Similarly, in multivariable analysis, total plaque volume index after intervention was significantly lowered as compared with intervention baseline level (P ¼ 0.013; Table 2 ).
Calcified Plaque
By univariable GEE analysis, calcified plaque volume index at intervention baseline was significantly higher as compared with preintervention level (P ¼ 0.014; Table 2); this relationship was maintained in multivariable models (P ¼ 0.048; Table 2 ). However, after intervention, calcified plaque volume was not significantly higher as compared with intervention baseline level in the multivariable analysis (P ¼ 0.20; Table 2 ).
Noncalcified Plaque
By univariable GEE analysis, noncalcified plaque volume index at intervention baseline was not significantly higher as compared with preintervention level (P ¼ 0.057; Table 2 ). In multivariable analysis, adjusting for preintervention plaque burden, the 2013 ACC/AHA-defined cardiovascular risk, and CRP, the difference in noncalcified plaque volume index from preintervention to intervention baseline was not significant (P ¼ 0.11; Table 2 ). However, after further adjustment for reduction in cocaine use, noncalcified plaque volume index at preintervention was significantly lowered as compared with intervention baseline level in the multivariable model (P ¼ 0.008; Table 3 ). Multivariable GEE analyses suggested that noncalcified plaque volume index at postintervention was significantly lowered as compared with intervention baseline level in the multivariable model (P ¼ 0.005, Table 2 ; and P ¼ 0.003, Table 3 ). FIGURE 2. Total coronary plaque volume index, calcified plaque volume index, and noncalcified plaque volume index over time. A, The mean total plaque volume indices were 39.0 (AESD 13.6) mm 2 for preintervention, 45.3 (AESD 11.4) mm 2 for intervention baseline, and 43.0 (AESD 11.7) mm 2 for postintervention, respectively. The difference between intervention baseline and postintervention was not significant (P ¼ 0.16, paired t test). B, The mean calcified plaque volume indies were 1.9 (AESD 3.7) mm 2 for preintervention, 3.8 (AESD 4.7) mm 2 for intervention baseline, and 3.9 (AESD 3.8) mm 2 for postintervention, respectively. The difference between intervention baseline and postintervention was not significant (P ¼ 0.83, paired t test). C, The mean noncalcified plaque volume indies were 37.1 (AESD 11.9) mm 2 for preintervention, 41.5 (AESD 9.0) mm 2 for intervention baseline, and 39.1 (AESD 9.8) mm 2 for postintervention, respectively. The difference between intervention baseline and postintervention was not significant (P ¼ 0.10, paired t test).
Changes in Coronary Plaque Burden and Changes in Cocaine Use Over Time
Total Plaque Volume
By univariable GEE analysis, changes in total plaque volume index was not significantly associated with reduction in cocaine use (P ¼ 0.11; Table 3 ). However, multivariable GEE analysis shows that after controlling for time variable, preintervention total plaque volume index, the 2013 ACC/AHA-defined cardiovascular risk, and CRP, reduction in cocaine use was significantly associated with a lower total plaque volume (P ¼ 0.019; Table 3 ).
Calcified Plaque
By univariable GEE analysis, changes in total calcified plaque volume index was not significantly associated with reduction in cocaine use (P ¼ 0.09; Table 3 ). Multivariable GEE analysis shows that after controlling for time variable, preintervention total calcified plaque volume index, the 2013 ACC/AHA-defined cardiovascular risk, and CRP, reduction in cocaine use was not significantly associated with a lower total plaque volume index (P ¼ 0.54; Table 3 ).
Noncalcified Plaque
By univariable GEE analysis, changes in total noncalcified plaque volume index was not significantly . During the 12 months of intervention, he used cocaine 77 days according to urine tests. The images show curved multiplanar reconstructions the LAD. Plaque in the arterial wall is defined by the outer vessel boundary (adventitia) and lumen boundary. On CCTA images the coronary tree was analyzed using the software QAngioCT (Medis, Leiden). A centerline is defined for each major vessel and vessel contours are defined using a semiautomatic method. CT: Siemens Flash, 120 kVp. Software: QAngio CT, Medis, Leiden, NL. Curved multiplanar reconstructions of the LAD in intervention baseline and 12-month follow-up examination with lumen/wall boundary (yellow line) and outer wall boundary (orange line) as detected by QAngioCT. Two mixed plaques in the proximal LAD are seen. A reduction of plaque volume from intervention baseline to postintervention is noted using plaque quantification. The red box indicates an area where plaque regression is seen on visual assessment. 
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Case Study
A case study demonstrating plaque regression from intervention baseline to postintervention is shown in Figure 1B . According to self-report data from questionnaires, the participant had used cocaine daily before intervention. 
DISCUSSION
The key findings of this investigation suggest that, whereas before intervention, coronary plaque burden, as measured by total coronary plaque volume index and noncalcified plaque volume index, significantly increased over approximately 4 years (from preintervention to intervention baseline), coronary plaque burden significantly decreased from the intervention baseline to postintervention after 12-month intervention in chronic cocaine users with obstructive coronary stenosis who never received any statin therapy. Furthermore, this study also suggests that reduced cocaine use may be significantly associated with lower total plaque volume index and noncalcified plaque volume index.
CAD usually begins with subclinical asymptomatic coronary atherosclerotic plaques accumulating in the vessel wall. After positive remodeling, these plaques may gradually compromise the coronary lumen, leading to luminal stenosis (Sakakura et al., 2013; Dalager et al., 2015; Schoenhagen and Yan, 2015) . The presence and extent of CAD on CCTA are strong, independent predictors of cardiovascular events (Bamberg et al., 2011) . Studies have demonstrated that probably owing to their biophysical properties, noncalcified plaques are considered more vulnerable and prone to rupture than are calcified plaques, which are viewed as more stable (Bauer et al., 2009; Hulten et al., 2011; Pasterkamp et al., 2000; Puri et al., 2013; Scott, 2004) . The data summarized in metaanalyses of studies with patients who underwent CCTA demonstrate that the extent of coronary plaque and stenosis, especially obstructive (>50% in diameter) coronary stenoses, is a strong independent predictor of future cardiovascular events (Huang et al., 2001; Pant et al., 2014) . A meta-analysis (N ¼ 7335 patients) demonstrated that compared with the absence of obstructive (>50%) coronary stenosis, the presence of obstructive coronary stenosis was associated with a 10-fold higher risk for all cardiovascular events (cardiovascular death, nonfatal myocardial infarction [MI] , unstable angina requiring hospitalization, and revascularization) and a 6-fold risk for death, MI, and unstable angina requiring hospitalization independent of the presence of coronary artery calcification (Bamberg et al., 2011) .
Coronary Plaque Progression
The results of this study demonstrate that after controlling for potential confounding factors, including preintervention plaque burden, cardiovascular risk defined by the 2013 ACC/AHA guidelines (Goff et al., 2014) , CRP, and reduction in cocaine use, total coronary plaque volume index and noncalcified plaque volume index at intervention baseline were significantly higher as compared with preintervention levels.
Since all the participants were not on any statin therapy, changes in coronary plaque burden in this time period could be regarded as the natural history of disease progression in asymptomatic chronic cocaine users with obstructive coronary stenosis. Despite the fact that the natural history of coronary atherosclerosis by CCTA in patients with clinical CAD is documented (Nicholls et al., 2010; Papadopoulou et al., 2012) , coronary plaque progression in those without cardiovascular symptoms has not been reported. Although our data revealed cardiovascular risk defined by the 2013 ACC/ AHA guidelines increased from preintervention to intervention baseline, it was not significant in GEE models, suggesting that conventional cardiovascular risk may not play an independent role in promoting plaque burden in this study population. The GEE analysis showed that CRP was independently associated with total plaque index and noncalcified plaque index, suggesting that CRP may play a significant role in disease progression.
Whereas several cross-sectional analyses observed a higher prevalence of atherosclerosis in cocaine users (Patrizi et al., 2006; Ebersberger et al., 2013) , data on longitudinal coronary changes are scarce. In a previous study, the authors followed 57 asymptomatic cocaine users with coronary plaque using contrast-enhanced CTA, and found that the incidence of coronary plaque progression, defined as the development of obstructive (>50%) coronary stenosis, was 15.1/100 person-years . It should be noted that the degree of coronary stenosis is not comparable with plaque volume as they represent different properties of the disease.
Coronary Plaque Regression
This study also shows that after controlling for potential confounding factors, including preintervention plaque burden, cardiovascular risk defined by the 2013 ACC/AHA guidelines, CRP, and reduction in cocaine use, total plaque volumes index, and noncalcified plaque volume index at postintervention were significantly lower compared with those at the intervention baseline, suggesting total plaque and noncalcified plaque regression during the 12-month intervention period. Furthermore, this study demonstrates that that reduced cocaine use may be significantly associated with lower total plaque volume index and noncalcified plaque volume index. These findings have not been reported in literature previously.
The exact mechanisms by which reduced cocaine use is associated with regression or arrest of progression of coronary plaque are not known, but inflammation appears to be a significant link. Inflammation has been associated with plaque progression (Puri et al., 2013) , and the pathophysiology of atherosclerosis with accumulation of inflammatory cells in the arterial wall has characteristics of an inflammatory process (Pant et al., 2014) . In this study, CRP levels were significantly reduced after the 12-month intervention (Fig. 2 , Table 1 ). Therefore, it appears plausible that lower levels of inflammation and endothelial damage, achieved by a reduction in cocaine use, are responsible for this favorable effect. Although several studies demonstrate that statin therapy reduces coronary plaque volume (Nicholls et al., 2011) , the participants in the present study never received statin therapy, further suggesting that reduced cocaine use may have reduced inflammation and endothelial damage, leading to stabilization or regression of coronary plaque.
It is worth nothing that according to the GEE analyses presented in Table 3 , CRP is not only a factor that was independently associated with both total plaque volume and noncalcified plaque volume, but also a negative confounding factor for the association of reduction in cocaine use with both total plaque volume and noncalcified plaque volume: in the univariable GEE analyses, reduction in cocaine use was not significant; however, the addition of CRP as a covariate in the multivariable GEE models resulted in significant regression coefficients for reduction in cocaine use. Statin adherence may be very poor in AA chronic cocaine users. It has been reported that the odds of nonadherence are 53% greater in non-white than in white patients (Kopjar et al., 2003; Lewey et al., 2013) , that statin adherence is also low in those with substance abuse (Kopjar et al., 2003) , and that outcomes in those with very low adherence to statin are worse than in those who never used statins (De Vera et al., 2014; Phan et al., 2014) .
Further studies are needed to explore the mechanisms underlying the association between reductions in cocaine use and changes in coronary plaque.
The findings of this investigation may have important implications for CAD prevention among cocaine users, especially for cocaine users with HIV infection. Cocaine use may not only promote coronary plaque progression, but also trigger/exacerbate adverse cardiovascular comorbidities induced by ART (Lai et al., 2016) .
To the best of our knowledge, this study is the first nonpharmaceutical investigation to explore whether abstinence from, or reduced, cocaine use yields beneficial cardiovascular effects, in particular, a reduction in coronary plaque burden in AA cocaine users with subclinical atherosclerosis.
Our study has several strengths that are mentioned as follows: progression of coronary plaque burden before intervention in the participants is known because of prior studies in those participants, allowing those data to more effectively assess the impact of the intervention; and coronary plaque analysis was used to quantify changes in coronary plaque burden. In previous analyses, all the CCTA outcome variables were based on coronary luminal stenosis quantification, not on coronary plaque quantification. Coronary stenosis quantification analysis provides useful information about 2D diameter stenosis; however, this analysis does not quantify and characterize coronary plaque progression/regression.
Limitations
This study has several limitations that must be acknowledged. First, this is a preliminary study with a small sample size and short follow-up time. Thus, we cannot exclude the possibility that our findings may be influenced by samplespecific distributions. Second, the study participants were not a random community sample. Thus, the study findings may have limited generalizability. Third, since the urine testing was scheduled in advance, and since the urine testing was not random, but scheduled in advance, some participants could have timed their cocaine use so as to avoid detection. Fourth, the study may have missed cocaine use episodes given the short half-life of cocaine (approximately 0.8 AE 0.2 hours) and benzoylecgonine (approximately 6 hours), and the fact urine was tested, at most, twice a week (eg, negative on Monday, used Tuesday, negative Thursday, used Friday/Saturday, negative on Monday, etc). Fifth, since 13 of the 15 participants were HIV-infected, the impact of HIV infection on coronary plaque burden could not be investigated. Sixth, we did not collect dietary data so that we could not exclude the possibility that dietary factor played some role. However, based on our previous dietary data collected based on 24-hour recall, there was little variation in dietary factors in this population. Seventh, since the urine testing was only used to determine whether participants had ''recently'' used cocaine, estimating reduction in cocaine use was based on an assumption that all the study participants had used cocaine daily before the intervention. Although questionnaire data suggested the study participants may have used cocaine daily, recall bias and other biases may occur. Eighth, reduction in cocaine use was defined as subtracted difference from 365 days of ''cumulative urine positive days during the 12-month intervention period according to urine tests.'' The 365 days of cocaine use is based on self-report, but the days of cocaine use during the 12-month intervention period are based on urine result. Lastly, as this study is not a randomized clinical trial, no causal inference can be drawn from these data.
CONCLUSIONS
These limitations notwithstanding, the findings of this study demonstrated a provocative association between reduced cocaine use and coronary plaque regression, and may have important implications for the prevention of cocaine-induced CAD. Also, since a large proportion of cocaine users have been infected with HIV, reducing cocaine use may retard HIV/ART-associated CAD. Further studies, especially randomized clinical trials, should be conducted to verify these findings.
In conclusion, reduced cocaine use, achieved during a 12-month intervention program, was associated with a significant reduction of noncalcified plaque volume index in AA chronic cocaine users. This preliminary study demonstrates potentially beneficial effects of cocaine abstinence/reduction on inflammation and coronary plaque phenotype.
